Earnings call transcript: Revvity Q1 2026 shows strong earnings beat

Revvity beat Q1 2026 expectations with adjusted EPS of $1.06 versus $1.02 consensus and revenue of $711 million versus $704.67 million, while adjusted operating margin reached 23.6%. The company also raised its pro forma 2026 outlook to $2.81 billion-$2.84 billion of revenue and $5.20-$5.30 of EPS, supported by the planned divestiture of its China immunodiagnostics business and ongoing share buybacks. Shares rose 1.14% pre-market on the results and improved outlook.

Analysis

RVTY is using the China diagnostics exit to clean up the story, but the bigger implication is capital efficiency: removing a structurally low-return, policy-sensitive business should mechanically lift the quality of every growth and margin metric investors underwrite. That matters because the stock’s multiple is more likely to rerate on the combination of cleaner organic growth, better conversion, and visible buyback capacity than on any single quarter beat. The immediate beneficiaries are shareholders via reduced earnings drag and a higher probability that incremental capital is deployed into repurchases or higher-ROIC tuck-ins rather than defensive capex.

The second-order effect is competitive. By stepping away from a capital-intensive local-China model, RVTY reduces exposure to a race-to-the-bottom market while competitors with less portfolio flexibility remain trapped defending share. Meanwhile, the company’s software and high-content screening momentum should benefit from a broader industry shift: AI is increasing the number of hypotheses generated, which raises downstream validation demand for reagents, instruments, and workflow software. In other words, AI may compress some discovery workflows, but it likely expands the spend pool in validation and data-generation tools where RVTY is positioned.

The main risk is that investors extrapolate the margin uplift too aggressively before the divestiture closes and before the cost actions are fully annualized. There is also a timing gap: the guide improvement is real, but the visible earnings uplift from portfolio actions and operational efficiencies is back-half weighted and can be derailed by weaker pharma/academic budgets or softer software comps. Near term, the setup is more about multiple expansion than estimate revisions; over the next 6-12 months, the key catalyst is whether organic growth stabilizes above 4% ex-China, which would validate the new baseline and likely force upward revisions to long-range assumptions.

Key Decisions for Investors

• Go long RVTY on pullbacks over the next 2-4 weeks; thesis is cleaner pro forma quality plus buyback optionality. Target 8-12% upside over 3-6 months if the market starts capitalizing the higher margin base; stop if pro forma growth slips back below 3% or software cadence deteriorates.
• Use RVTY September/January call spreads to express the rerating story with limited downside. Favor strikes around 5-10% above spot to monetize a medium-term multiple expansion driven by portfolio simplification and margin visibility.
• Pair trade: long RVTY / short a diagnostics name with higher China policy exposure and weaker software exposure over the next 1-2 quarters. The relative trade should work if investors reward cleaner geographic mix and penalize firms still defending structurally challenged China diagnostics assets.
• Add to RVTY only if the market overreacts to the Q2 software step-down. That dip looks more like a comp artifact than a demand issue; if shares sell off on the quarter, use it as an entry point rather than chasing post-earnings strength.
• For event-driven accounts, monitor the divestiture agreement timing as the next catalyst. A definitive deal within the next 1-2 months would de-risk the rerate; if delayed, fade the stock on any move that assumes 2026 EPS uplift arrives earlier than 2027.